| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
|
N Engl J Med
|
2004
|
49.02
|
|
2
|
MGMT gene silencing and benefit from temozolomide in glioblastoma.
|
N Engl J Med
|
2005
|
29.65
|
|
3
|
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
|
J Clin Oncol
|
2000
|
16.83
|
|
4
|
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
|
J Clin Oncol
|
2003
|
12.82
|
|
5
|
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
|
Lancet
|
2000
|
12.56
|
|
6
|
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
|
J Clin Oncol
|
2004
|
7.04
|
|
7
|
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
|
Lancet Oncol
|
2012
|
5.86
|
|
8
|
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
|
Clin Cancer Res
|
2007
|
4.99
|
|
9
|
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
|
N Engl J Med
|
2014
|
4.81
|
|
10
|
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
|
Br J Cancer
|
1992
|
2.91
|
|
11
|
Balancing repair and tolerance of DNA damage caused by alkylating agents.
|
Nat Rev Cancer
|
2012
|
2.52
|
|
12
|
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
|
Ann Oncol
|
2014
|
2.31
|
|
13
|
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
|
Lancet Oncol
|
2010
|
1.97
|
|
14
|
Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
|
J Invest Dermatol
|
2012
|
1.90
|
|
15
|
Carcinogen-specific induction of genetic instability.
|
Proc Natl Acad Sci U S A
|
2001
|
1.76
|
|
16
|
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
|
J Clin Oncol
|
1997
|
1.76
|
|
17
|
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes.
|
Curr Opin Genet Dev
|
2013
|
1.62
|
|
18
|
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
|
Oncogene
|
2004
|
1.49
|
|
19
|
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.
|
Cancer Chemother Pharmacol
|
2013
|
1.28
|
|
20
|
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2002
|
1.27
|
|
21
|
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
|
Clin Cancer Res
|
2000
|
1.27
|
|
22
|
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
|
Ann Oncol
|
2004
|
1.11
|
|
23
|
Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.
|
Cancer Res
|
2001
|
1.06
|
|
24
|
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
|
Clin Cancer Res
|
2000
|
1.00
|
|
25
|
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.
|
Ann Oncol
|
2013
|
0.94
|
|
26
|
Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.
|
J Exp Med
|
2004
|
0.88
|
|
27
|
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
|
Eur J Cancer
|
2016
|
0.87
|
|
28
|
A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
|
Mol Cancer Ther
|
2013
|
0.83
|
|
29
|
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
|
Ann Oncol
|
2016
|
0.82
|
|
30
|
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer.
|
Target Oncol
|
2016
|
0.77
|
|
31
|
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
|
Eur J Cancer
|
2016
|
0.77
|
|
32
|
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
|
Eur J Cancer
|
2016
|
0.75
|
|
33
|
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
|
Br J Cancer
|
2017
|
0.75
|
|
34
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
|
Nature
|
2017
|
0.75
|